Cytostatic effect of xanthone-loaded mPEG-b-p(HPMAm-Lac 2) micelles towards doxorubicin sensitive and resistant cancer cells

Colloids and Surfaces B: Biointerfaces

Volumn 94, Issue , 2012, Pages 266-273

  Khonkarn, Ruttiros ^a   Mankhetkorn, Samlee ^a   Talelli, Marina ^b   Hennink, Wim E ^b   Okonogi, Siriporn ^a  

^a CHIANG MAI UNIVERSITY   (Thailand)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anticancer; Apoptosis; Cytotoxicity; Polymeric micelle; Xanthone

Indexed keywords

ANTICANCER; ANTICANCER ACTIVITIES; AQUEOUS SOLUBILITY; CANCER CELL LINES; CANCER CELLS; CYTOSTATIC; DELIVERY SYSTEMS; DOXORUBICIN; ENTRAPMENT EFFICIENCY; FLOW-CYTOMETRIC ANALYSIS; FREEFORMS; GROWTH INHIBITION; IN-VITRO ASSAYS; LOADING CAPACITIES; PARTICLE DIAMETERS; POLYMERIC MICELLE; PROPIDIUM IODIDE; XANTHONE;

CELL CULTURE; CELL DEATH; CYTOTOXICITY; MOTION PICTURE EXPERTS GROUP STANDARDS; POLYETHYLENE GLYCOLS; POLYMERS;

MICELLES;

ANTINEOPLASTIC AGENT; DOXORUBICIN; DRUG CARRIER; POLY(ETHYLENE GLYCOL) B POLY[N(2 HYDROXYPROPYL)METHACRYLAMIDE DILACTATE]; PROPIDIUM IODIDE; UNCLASSIFIED DRUG; XANTHONE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CELL COUNT; CELL CYCLE CHECKPOINT; CELL CYCLE G0 PHASE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRITICAL MICELLE CONCENTRATION; CYTOSTASIS; DNA CONTENT; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG MECHANISM; DRUG RELEASE; DRUG STABILITY; FLOW CYTOMETRY; G0 PHASE CELL CYCLE CHECKPOINT; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MICELLE; PARTICLE SIZE; PRIORITY JOURNAL;

APOPTOSIS; CELL LINE, TUMOR; CELL SURVIVAL; CYTOSTATIC AGENTS; DOXORUBICIN; DRUG CARRIERS; DRUG COMPOUNDING; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; KINETICS; LEUKOCYTES, MONONUCLEAR; MICELLES; NEOPLASMS; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYMETHACRYLIC ACIDS; PROPIDIUM; SOLUBILITY; XANTHONES;

EID: 84859157763     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2012.02.002     Document Type: Article

References (42)

1. Heffeter P., Jakupec M.A., Karner W., Chiba P., Pirker C., Dornetshuber R., Elbling L., Sutterluty H., Micksche M., Keppler B.K., Berger W. Biochem. Pharmacol. 2007, 73:1873.
2. Pavlidis N.A., Tolis C.F., Briassoulis E.C., Sourla A., Klouvas G.D. Lung Cancer 1991, 7:279.
3. Chen L.G., Yang L.L., Wang C.C. Food Chem. Toxicol. 2008, 46:688.
4. Mahabusarakam W., Proudfoot J., Taylor W., Croft K. Free Radic. Res. 2000, 33:643.
5. Pedraza-Chaverri J., Cardenas-Rodriguez N., Orozco-Ibarra M., Perez-Rojas J.M. Food Chem. Toxicol. 2008, 46:3227.
6. Sakagami Y., Iinuma M., Piyasena K.G.N.P., Dharmaratne H.R.W. Phytomedicine 2005, 12:203.
7. Edwards J., Pappa G., Torok M., Fowler A., Bausch J. Toxicol. Lett. 2009, 189:S144.
8. Gelderblom H., Verweij J., Nooter K., Sparreboom A. Eur. J. Cancer 2001, 37:1590.
9. Li Y., Xiao K., Luo J., Lee J., Pan S., Lam K.S. J. Control. Release 2010, 144:314.
10. Kedar U., Phutane P., Shidhaye S., Kadam V. Nanomed-Nanotechnol. 2010, 6:714.
11. Watanabe M., Kawano K., Yokoyama M., Opanasopit P., Okano T., Maitani Y. Int. J. Pharm. 2006, 308:183.
12. Oerlemans C., Bult W., Bos M., Storm G., Nijsen J., Hennink W. Pharm. Res. 2010, 27:2569.
13. Kataoka K., Harada A., Nagasaki Y. Adv Drug Deliver Rev. 2001, 47:113.
14. Jones M.C., Leroux J.C. Eur. J. Pharm. Biopharm. 1999, 48:101.
15. Molavi O., Ma Z., Mahmud A., Alshamsan A., Samuel J., Lai R., Kwon G.S., Lavasanifar A. Int. J. Pharm. 2008, 347:118.
16. Maeda H. J. Control. Release 2010, 142:296.
17. Soga O., van Nostrum C.F., Hennink W.E. Biomacromolecules 2004, 5:818.
18. Soga O., van Nostrum C.F., Ramzi A., Visser T., Soulimani F., Frederik P.M., Bomans P.H.H., Hennink W.E. Langmuir 2004, 20:9388.
19. Rijcken C.J.F., Hofman J.-W., van Zeeland F., Hennink W.E., van Nostrum C.F. J. Control. Release 2007, 124:144.
20. Talelli M., Rijcken C.J.F., van Nostrum C.F., Storm G., Hennink W.E. Adv. Drug Deliv. Rev. 2010, 62:231.
21. Kopeček J., Kopečková P. Adv. Drug Deliv. Rev. 2010, 62:122.
22. Soga O., van Nostrum C.F., Fens M., Rijcken C.J.F., Schiffelers R.M., Storm G., Hennink W.E. J. Control. Release 2005, 103:341.
23. Rijcken C.J., Snel C.J., Schiffelers R.M., van Nostrum C.F., Hennink W.E. Biomaterials 2007, 28:5581.
24. Asai F., Tosa H., Tanaka T., Iinuma M. Phytochemistry 1995, 39:943.
25. Khonkarn R., Mankhetkorn S., Hennink W.E., Okonogi S. Eur. J. Pharm. Biopharm. 2011, 79:268.
26. Tennant J.R. Transplantation 1964, 2:685.
27. Alley M.C., Scudiero D.A., Monks A. Cancer Res. 1988, 48:589.
28. Panyam J., Labhasetwar V. Mol. Pharmacol. 2004, 1:77.
29. W. Suttana, Ph.D. Dissertation, Chiang Mai University, Chiang Mai, Thailand, 2009.
30. Dyuzheva M.S., Kargu O.V., Klyubin V.V. Colloid J. 2002, 64:33.
31. Danial N.N., Korsmeyer S.J. Cell 2004, 116:205.
32. Ruggieri A., Trani L.D., Gatto I., Franco M., Vignolo E., Bedini B., Elia G., Buonavoglia C. Vet. Microbiol. 2007, 121:64.
33. Li F., Li J., Wen X., Zhou S., Tong X., Su P., Li H., Shi D. Mater. Sci. Eng. C 2009, 29:2392.
34. de Jong S.J., Arias E.R., Rijkers D.T.S., van Nostrum C.F., Kettenes-van den Bosch J.J., Hennink W.E. Polymer 2001, 42:2795.
35. Matsumoto K., Akao Y., Kobayashi E., Ohguchi K., Ito T., Tanaka T., Iinuma M., Nozawa Y. J. Nat. Prod. 2003, 66:1124.
36. Matsumoto K., Akao Y., Yi H., Ohguchi K., Ito T., Tanaka T., Kobayashi E., Iinuma M., Nozawa Y. Bioorg. Med. Chem. 2004, 12:5799.
37. Matsumoto K., Akao Y., Ohguchi K., Ito T., Tanaka T., Iinuma M., Nozawa Y. Bioorg. Med. Chem. 2005, 13:6064.
38. Suksamrarn S., Komutiban O., Ratananukul P., Chimnoi N., Lartpornmatulee N., Suksamrarn A. Chem. Pharm. Bull. 2006, 54:301.
39. Surti N., Naik S., Bagchi T., Dwarkanath B.S., Misra A. AAPS PharmSciTech. 2008, 9:217.
40. Suh H., Jeong B., Rathi R., Kiml S.W. J. Biomed. Mater. Res. 1998, 42:331.
41. Park J.S., Han T.H., Lee K.Y., Han S.S., Hwang J.J., Moon D.H., Kim S.Y., Cho Y.W. J. Control. Release 2006, 115:37.
42. Lee E.S., Na K., Bae Y.H. J. Control. Release 2005, 103:405.